With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company...Read more
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1 EAST HANOVER, N.J., July 3, 2025 /PRNewswire/...Read more
4FRONT-1 Phase 3 expected data readout accelerated from H2 2027 to H1 2027 4FRONT-2 Phase 3 trial initiated ahead of schedule Streamlined late-stage clinical and pre-commercial organization aligns with focused pipeline shift, as announced in January 2025 EMERYVILLE, Calif.,...Read more
Company will be seeking alignment to begin rolling BLA submission NEW YORK / Jul 03, 2025 / Business Wire / OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced it was granted...Read more
TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple...Read more
PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for...Read more
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| McKesson | 12.56 1.78 | $718.01 |
| Regencell Bioscience | 9.96 96.14 | $20.32 |
| Regeneron Pharmaceuticals | 7.20 1.31 | $554.94 |
| SciSparc | 6.24 2,010.86 | $6.55 |
| Bolt Biotherapeutics | 5.36 959.03 | $5.92 |
| Instil Bio | 4.46 18.75 | $28.25 |
| IDEXX Laboratories | 4.30 0.79 | $547.01 |
| Insmed | 3.76 3.83 | $102.00 |
| Chemed | 3.56 0.76 | $474.80 |
| Stryker | 3.46 0.88 | $395.27 |
| Mettler-Toledo | 3.43 0.28 | $1,209.08 |
| Intuitive | 3.29 0.61 | $543.89 |
| Krystal Biotech | 3.16 2.24 | $144.51 |
| Cardinal Health | 2.79 1.72 | $164.77 |
| Pro-Dex | 2.77 6.15 | $47.82 |
| Belite Bio | 2.66 4.68 | $59.47 |
| Apogee Therapeutics | 2.46 5.55 | $46.78 |
| Quest Diagnostics | 2.40 1.36 | $179.00 |
| Company | Volume | Last Trade |
|---|---|---|
| Healthcare Triangle | 136,790,997 | $0.03 |
| Windtree Therapeutics | 80,802,109 | $0.91 |
| LIXTE Biotechnology | 63,960,829 | $2.65 |
| Electromedical Technologies | 44,210,000 | $0.00 |
| Clearmind Medicine | 41,617,989 | $1.09 |
| NuCana | 41,560,866 | $0.06 |
| OS Therapies | 38,052,498 | $1.88 |
| Centene | 29,271,459 | $33.24 |
| Oscar Health | 25,641,547 | $16.53 |
| Vor Bio | 24,317,808 | $1.87 |
| Pfizer | 21,026,988 | $25.44 |
| INOVIO | 20,268,441 | $1.40 |
| Regencell Bioscience | 18,609,514 | $20.32 |
| MIRA Pharmaceuticals | 18,507,249 | $1.16 |
| Recursion | 16,506,870 | $5.24 |
| PacBio | 13,668,877 | $1.61 |
| Quantum-Si | 12,675,821 | $2.11 |
| Summit Therapeutics | 12,617,950 | $24.40 |
| Exelixis | 11,701,665 | $46.15 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
